Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C) (Q60683147)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

Brad H Nelson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

author name string

Darin A Wick

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

John R Webb

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

language of work or name

English

0 references

publication date

January 2011

0 references

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

page(s)

984-993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo

25 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

CD8+ T cell efficacy in vaccination and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Strategies for designing and optimizing new generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Vaccines: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Viruses as vaccine vectors for infectious diseases and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Heterologous prime-boost vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Design and development of synthetic peptide vaccines: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Viral immunity: cross-priming with the help of TLR3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

CD8 T cell expansion and memory differentiation are facilitated by simultaneous and sustained exposure to antigenic and inflammatory milieu.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Exuberated numbers of tumor-specific T cells result in tumor escape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Cancer immunoediting: from immunosurveillance to tumor escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Twelve immunotherapy drugs that could cure cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Jump-starting the immune system: prime-boosting comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

A comparison and critical analysis of preclinical anticancer vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.036

10.1016/J.VACCINE.2010.11.036

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21115055%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

1 reference